SCHEMBL22800960

SCHEMBL22800960

Cn1c(=O)[nH]c(=O)c2c1nc(N1CCN(CCc3ccc(C(C)(C)C)cc3)CC1)n2Cc1ccccc1F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 1/20 0.59
▸ MEN1 O00255 2/20 0.58
▸ KMT2A Q03164 2/20 0.58
▸ ALDH1A1 P00352 8/20 0.58
▸ GLA P06280 1/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ HTT P42858 5/20 0.57
▸ POLB P06746 2/20 0.56
▸ TP53 P04637 1/20 0.55
▸ GAA P10253 3/20 0.55
▸ HSD17B10 Q99714 2/20 0.55
▸ LMNA P02545 1/20 0.55
▸ MAPT P10636 1/20 0.55
▸ NPSR1 Q6W5P4 1/20 0.55
▸ TSHR P16473 4/20 0.55
▸ HPGD P15428 1/20 0.55
▸ USP2 O75604 3/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ DPP4 P27487 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22800971 0.93 ALDH1A1 (0.62) PKMMEN1KMT2AALDH1A1GLA
SCHEMBL22800987 0.89 PKM (0.64) PKMMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL22828420 0.87 MEN1 (0.48) PKMMEN1KMT2AALDH1A1GLA
SCHEMBL22800946 0.87 PKM (0.57) PKMMEN1KMT2AALDH1A1GLA
SCHEMBL22800942 0.87 MEN1 (0.61) PKMMEN1KMT2AALDH1A1GLA
SCHEMBL22800966 0.87 ALDH1A1 (0.62) PKMMEN1KMT2AALDH1A1GLA
SCHEMBL22800911 0.86 PKM (0.57) PKMMEN1KMT2AALDH1A1GLA
SCHEMBL22800921 0.85 ALDH1A1 (0.57) PKMMEN1KMT2AALDH1A1GLA
SCHEMBL22800961 0.85 ALDH1A1 (0.66) PKMMEN1KMT2AALDH1A1GLA
SCHEMBL22800922 0.83 PKM (0.68) PKMMEN1KMT2AALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11578073-B2 Xanthine analogs as potent anti-West Nile viral agents SOUTHERN RESEARCH INSTITUTE (US) 2023-02-14 — — US disclosed
US-11578073-B2 Xanthine analogs as potent anti-West Nile viral agents SOUTHERN RESEARCH INSTITUTE (US) 2023-02-14 — — US disclosed
US-20200399271-A1 XANTHINE ANALOGS AS POTENT ANTI-WEST NILE VIRAL AGENTS OREGON HEALTH AND SCIENCE UNIVERSITY 2020-12-24 — — US disclosed
US-20200399271-A1 XANTHINE ANALOGS AS POTENT ANTI-WEST NILE VIRAL AGENTS OREGON HEALTH AND SCIENCE UNIVERSITY 2020-12-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399271-A1 XANTHINE ANALOGS AS POTENT ANTI-WEST NILE VIRAL AGENTS XDH, PNP, MAVS PKM 1096/4885MEN1 4456/4885KMT2A 2568/4885
US-11578073-B2 Xanthine analogs as potent anti-West Nile viral agents XDH, PNP, MAVS PKM 1096/4885MEN1 4456/4885KMT2A 2568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback